Bopindolol Malonate | CAS#82857-38-3 (malonate) | 62658-64-4 | Adrenoceptor Antagonist

MedKoo Cat#: 317330 | Name: Bopindolol Malonate

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Bopindolol malonate is a non-selective, potent, long-acting beta adrenoceptor antagonist. It demonstrates inhibition of H2O2-induced lipid peroxdiation. Bopindolol malonate slowly dissociates into the active metabolites 4-(3-tert-butylamino-2-hydroxypropoxy)-2-methyl indole and 4-(3-tert-butylaminopropoxy)-2-carboxyl indole which both demonstrate potent β1-adrenoceptor blocking activity.

Chemical Structure

Bopindolol Malonate

CAS#82857-38-3 (malonate)

Theoretical Analysis

MedKoo Cat#: 317330

Name: Bopindolol Malonate

CAS#: 82857-38-3 (malonate)

Chemical Formula: C26H32N2O7

Exact Mass: 0.0000

Molecular Weight: 484.54

Elemental Analysis: C, 64.45; H, 6.66; N, 5.78; O, 23.11

Price and Availability

Size	Price	Availability	Quantity
100mg	USD 350.00	2 Weeks
500mg	USD 850.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

62658-63-3 (free base) 79125-22-7 (furamate) 82857-38-3 (malonate)

Synonym

Bopindolol Malonate; Bopindolol malonate; AC1LCS45; SCHEMBL348872; CTK8F8315; HE393689; LS-120081; D01794; Sandonorm; Bopindolol hydrogen malonate; Wandonorm; Sandonorm (TN)

IUPAC/Chemical Name

[1-(tert-butylamino)-3-[(2-methyl-1H-indol-4-yl)oxy]propan-2-yl] benzoate;propanedioic acid

InChi Key

LDOONRJGLKHGJI-UHFFFAOYSA-N

InChi Code

InChI=1S/C23H28N2O3.C3H4O4/c1-16-13-19-20(25-16)11-8-12-21(19)27-15-18(14-24-23(2,3)4)28-22(26)17-9-6-5-7-10-17;4-2(5)1-3(6)7/h5-13,18,24-25H,14-15H2,1-4H3;1H2,(H,4,5)(H,6,7)

SMILES Code

CC1=CC2=C(N1)C=CC=C2OCC(CNC(C)(C)C)OC(=O)C3=CC=CC=C3.C(C(=O)O)C(=O)O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Certificate of Analysis

View CoA: current batch, Lot#C9M09C21

Safety Data Sheet (SDS)

View Safety Data Sheet (SDS)

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 484.54 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Belal F, Sharaf El-Din M, Aly F, Hefnawy M, El-Awady M. Fluorometric determination of bopindolol and celiprolol in pharmaceutical preparations and biological fluids. J Fluoresc. 2012 Jul;22(4):1141-50. doi: 10.1007/s10895-012-1053-1. Epub 2012 Apr 3. PubMed PMID: 22477063. 2: Meireles J, Sklenárová H, Satínský D, Solich P, Araújo AN, Montenegro MC. Determination of bopindolol using the flow injection technique coupled with solid phase extraction. J Pharm Biomed Anal. 2003 Dec 4;33(5):1149-53. PubMed PMID: 14656606. 3: Satínský D, Sklenárová H, Huclová J, Karlícek R. Determination of bopindolol by sequential injection technique with spectrophotometric detection. Farmaco. 2003 Oct;58(10):1057-62. PubMed PMID: 14505739. 4: Kruk I, Michalska T, Kladna A, Aboul-Enein HY. Spin trapping study of reactive oxygen species formation during bopindolol peroxidation. Biopolymers. 2002 Oct 15;65(2):89-94. PubMed PMID: 12209459. 5: Urbánek M, Pospísilová M, Polásek M. Determination of bopindolol in pharmaceuticals by capillary isotachophoresis. J Pharm Biomed Anal. 2002 May 15;28(3-4):509-15. PubMed PMID: 12008130. 6: Nagatomo T, Hosohata Y, Ohnuki T, Nakamura T, Hattori K, Suzuki J, Ishiguro M. Bopindolol: pharmacological basis and clinical implications. Cardiovasc Drug Rev. 2001 Spring;19(1):9-24. Review. PubMed PMID: 11314603. 7: Nakamura T, Suzuki A, Ohnuki T, Hattori K, Watanabe K, Kurose H, Nagao T, Nagatomo T. Assessment of affinities of propranolol and bopindolol to membranes from COS-7 cell transiently transfected with beta-1- and beta-2-adrenoceptors using a radioligand-binding assay method. Pharmacology. 2000 Jul;61(1):6-10. PubMed PMID: 10895074. 8: Hattori K, Suzuki J, Hosohata Y, Ohnuki T, Nakamura T, Watanabe K, Muramatsu I, Nagatomo T. Sustaining effects of bopindolol on inhibitory chronotropic actions in guinea pig atria. Pharmacology. 1999 Oct;59(4):183-91. PubMed PMID: 10474078. 9: Hattori K, Ishiguro M, Ohnuki T, Nakamura T, Muramatsu I, Nagatomo T. Identification of binding sites of bopindolol and its two metabolites with beta1-adrenoceptors by molecular modeling: comparison with beta2 adrenoceptors. Pharmacology. 1999 Apr;58(4):183-9. PubMed PMID: 10077737. 10: Hosohata Y, Hattori K, Shen Y, Okuyama M, Kaneko H, Ohnuki T, Suzuki J, Nagatomo T. Bopindolol: a slowly dissociating antagonist from the beta-adrenoceptors in guinea pig atria. Pharmacology. 1998 Oct;57(4):180-7. PubMed PMID: 9730775. 11: Aboul-Enein HY, Kruk I, Lichszteld K. Chemiluminescence accompanying oxidation of bopindolol. Biospectroscopy. 1998;4(4):229-33. PubMed PMID: 9706382. 12: Bagatin J, Sardelić S, Pivac N, Polić S, Ljutic D, Rakic D, Naranca M, Bojić L, Kovacić Z, Rumboldt Z. Comparison of chlorthalidone, propranolol and bopindolol in six-month treatment of arterial hypertension. Int J Clin Pharmacol Res. 1998;18(2):73-8. PubMed PMID: 9675624. 13: Nagatomo T, Ishiguro M, Ohnuki T, Hattori K, Hosohata Y, Takatsu N, Katayama H, Watanabe K. Studies on relationships between chemical structure and beta-blocking potency of bopindolol and its two metabolites. Life Sci. 1998;62(17-18):1597-600. PubMed PMID: 9585142. 14: Nagatomo T, Hosohata Y, Ohnuki T, Suzuki J. [Pharmacological characteristics of the long-acting beta-blocker "bopindolol"]. Nihon Yakurigaku Zasshi. 1997 Jan;109(1):1-12. Review. Japanese. PubMed PMID: 9067994. 15: Hosohata Y, Sasaki K, Maruyama K, Ohnuki T, Hattori K, Suzuki J, Watanabe K, Nagatomo T. Effects of chronic administration of bopindolol on the binding characteristics of cardiac alpha 1H-, alpha 1L-, beta 1- and beta 2-adrenoceptor subtypes in cardiac muscles of spontaneously hypertensive rats (SHR). Biol Pharm Bull. 1996 Jul;19(7):932-5. PubMed PMID: 8839963. 16: Widimský J, Lánská V, Hulínský V, Balazovjech I, Havlík V, Havránek P, Kroupa E, Nikodýmová L, Pátek F, Svítil F, Svihovcová P. [Treatment of hypertension with a fixed combination of bopindolol and chlorthalidone (Sandoretic)]. Vnitr Lek. 1996 Apr;42(4):223-8. Czech. PubMed PMID: 8693706. 17: Hosohata Y, Sasaki K, Shen Y, Hattori K, Suzuki J, Nagatomo T. Bopindolol is a slowly dissociating beta 1-adrenoceptor antagonist when compared to other beta-blockers. Biol Pharm Bull. 1995 Aug;18(8):1066-71. PubMed PMID: 8535397. 18: Hosohata Y, Sasaki K, Suzuki M, Karakisawa Y, Maruyama K, Tsuchihashi H, Nagatomo T. Alpha-1 and beta-adrenergic receptor blocking potencies of bopindolol and its two metabolites (18-502 and 20-785) as assessed by radioligand binding assay methods. Gen Pharmacol. 1995 Jul;26(4):743-7. PubMed PMID: 7635249. 19: Aniya Y, Fong KF, Naito A, Sakanashi M. Antioxidative action of the beta-adrenoceptor antagonist bopindolol and its metabolite 18-502. Jpn J Pharmacol. 1995 Jul;68(3):323-9. PubMed PMID: 7474556. 20: Hosohata Y, Suzuki M, Karakisawa Y, Maruyama K, Nagatomo T. The affinity of bopindolol and its two metabolites for a beta 2-adrenoceptor in the bovine mesenteric artery. Biol Pharm Bull. 1994 Sep;17(9):1296-8. PubMed PMID: 7841957.